



ASX Announcement

23 May 2023

2023 Annual General Meeting Results

Melbourne, Australia, 23 May 2023 – In accordance with ASX Listing Rule 3.13.2 and section 251AA of the *Corporations Act 2001 (Cth)*, Avecho Biotechnology Limited (ASX: AVE) advises that the details of the resolutions and the proxies received in respect of each resolution at its Annual General Meeting today are set out in the attached proxy summary.

For enquiries, please contact

Melanie Leydin
Company Secretary
+61 3 9692 7222

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

About Avecho

Avecho Biotechnology Limited (ASX: AVE) develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called TPM®. TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market and is also developing TPM® to enhance the feed efficiency and health of livestock. New additions to the development program include the recently announced application of TPM® to cannabinoids.

See more here - avecho.com.au

**Annual General Meeting
Tuesday 23 May 2023
Voting Results**

The following information is provided in accordance with section 251AA(2) of Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution Details				Show of Hands (S) or Poll (P)	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution		Resolution Type	If s259U applies		For	Against	Proxy's Discretion	Abstain	For	Against	Abstain	Carried/ Not Carried
1	Adoption of Remuneration Report	Ordinary	N/A	P	215,285,950 94.77%	3,868,748 1.70%	8,009,657 3.53%	2,692,416 -	544,377,394 99.29%	3,868,748 0.71%	2,692,416 -	Carried
2	Re-Election of Dr Gregory Collier as a Director of the Company	Ordinary	N/A	P	238,623,222 96.61%	546,225 0.22%	7,829,657 3.17%	291,841 -	583,117,998 99.91%	546,225 0.09%	291,841 -	Carried
3	Re-Election of Mr Matthew Patrick McNamara as a Director of the Company	Ordinary	N/A	P	236,627,222 95.80%	642,225 0.26%	9,729,657 3.94%	291,841 -	567,717,720 97.27%	15,946,503 2.73%	291,841 -	Carried
4	Renewal of Avecho Biotechnology Limited Equity Incentive Plan	Ordinary	N/A	P	214,597,045 93.81%	6,482,036 2.83%	7,683,824 3.36%	18,528,040 -	543,362,656 98.82%	6,482,036 1.18%	18,528,040 -	Carried
5a	Approval for the issue of JLM Options to CoPeak Corporate Pty Ltd	Ordinary	N/A	P	147,523,705 91.69%	5,287,036 3.29%	8,078,026 5.02%	86,402,178 -	426,508,027 85.72%	71,045,859 14.28%	86,402,178 -	Carried
5b	Approval for the issue of JLM Options to CPS Capital Group Pty Ltd	Ordinary	N/A	P	146,941,705 91.47%	5,127,036 3.19%	8,574,657 5.34%	86,647,547 -	426,422,658 85.75%	70,885,859 14.25%	86,647,547 -	Carried
5c	Ratify the issue of JLM Options to CoPeak Corporate Pty Ltd	Ordinary	N/A	N/A	This motion was withdrawn as announced on 18 May 2023.							N/A
5d	Ratify the issue of JLM Options to CPS Capital Group Pty Ltd	Ordinary	N/A	N/A	This motion was withdrawn as announced on 18 May 2023.							N/A
6	Approval of 10% Placement Facility	Special	N/A	P	232,920,787 94.51%	2,550,437 1.03%	11,010,055 4.46%	809,666 -	580,595,961 99.56%	2,550,437 0.44%	809,666 -	Carried

*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.